the campaign. what are we seeing with drug pricing in a republican-controlled congress? oliver: as we talked about coming into this year, the folks that we saw involved, whether it be congress, the senate, or in terms of the individuals were health and human services, really focused on market-driven solutions to pricing. we have seen that in terms of, for instance, the fda focused on getting drugs approved quicker. a little bit of an impact already. we think that there are market-driven forces continuing. as i mentioned, we have seen pressure on some of the companies, especially in the pharma space, that took large price increases, that icing pressure now. vonnie: can you give me the percentage you are long and short? oliver: pretty even where we normally are, 50% net.